Future of 5-fluorouracil in cancer therapeutics, current pharmacokinetics issues and a way forward

SZ. Iqbal, F. Jubeen, F. Sher

Research output: Contribution to journalArticle

Abstract

Background: In addition to exhibiting antitumor potential, antitumor drugs exhibit toxicity due to a poor pharmacokinetic profile. An enormous amount of research has been carried out and is still ongoing to obtain more targeted, potent, and safe drugs to treat cancer, and pharmacokinetic evaluations of anticancer drugs are needed. Objectives: The present review examined different delivery systems and methodologies designed in recent years to investigate the pharmacokinetics of the anticancer drug, 5-fluorouracil (5-FU). These methodologies highlight how the issues of bioavailability, absorption, half-life, targeted neoplastic cell potential, and high therapeutic index of 5-FU are resolved. Results: A number of naturally occurring macromolecules such as modified starch, porphyran, peptides, and folic acids have been found to be successful in vitro to improve the permeability and retention effect of 5-FU against solid tumors. A promising approach for targeted 5-FU delivery to oncoproteins has resulted in a number of potentially sound anticancer nanocomposites. Chitosan nanoparticles loaded with 5-FU have been shown to exhibit cytotoxicity equivalent to 5-FU injections against gastric carcinoma. At the level of inter- and intra-molecular interactions, the co-crystal approach has been found to be successful against colorectal cancer proteins. Because of the 5-FU ligand-like nature and its metal-binding potential, researchers have shifted attention toward the synergistic co-administration of gold complexes with this drug. Conclusions: This study highlighted the techniques used to improve the pharmacokinetics of 5-FU and that “nanocarriers” are a promising approach in this field. The conclusion is supported by solid evidence.
Original languageEnglish
Pages (from-to)155-161
Number of pages7
JournalJournal of Cancer Research and Practice
Volume6
Issue number4
DOIs
Publication statusPublished - 23 Sep 2019

Fingerprint

Fluorouracil
Pharmacokinetics
Neoplasms
Therapeutics
Pharmaceutical Preparations
Nanocomposites
Drug Evaluation
Oncogene Proteins
Chitosan
Drug-Related Side Effects and Adverse Reactions
Folic Acid
Gold
Starch
Antineoplastic Agents
Nanoparticles
Biological Availability
Half-Life
Colorectal Neoplasms
Permeability
Stomach

Bibliographical note

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit
is given and the new creations are licensed under the identical terms.

Keywords

  • Delivery systems
  • nanocomposites
  • pharmacokinetic targeted potentials
  • prodrug

Cite this

Future of 5-fluorouracil in cancer therapeutics, current pharmacokinetics issues and a way forward. / Iqbal, SZ.; Jubeen, F.; Sher, F.

In: Journal of Cancer Research and Practice, Vol. 6, No. 4, 23.09.2019, p. 155-161.

Research output: Contribution to journalArticle

@article{b0005c1ffebc4140b8cd1c0a6cfcf23d,
title = "Future of 5-fluorouracil in cancer therapeutics, current pharmacokinetics issues and a way forward",
abstract = "Background: In addition to exhibiting antitumor potential, antitumor drugs exhibit toxicity due to a poor pharmacokinetic profile. An enormous amount of research has been carried out and is still ongoing to obtain more targeted, potent, and safe drugs to treat cancer, and pharmacokinetic evaluations of anticancer drugs are needed. Objectives: The present review examined different delivery systems and methodologies designed in recent years to investigate the pharmacokinetics of the anticancer drug, 5-fluorouracil (5-FU). These methodologies highlight how the issues of bioavailability, absorption, half-life, targeted neoplastic cell potential, and high therapeutic index of 5-FU are resolved. Results: A number of naturally occurring macromolecules such as modified starch, porphyran, peptides, and folic acids have been found to be successful in vitro to improve the permeability and retention effect of 5-FU against solid tumors. A promising approach for targeted 5-FU delivery to oncoproteins has resulted in a number of potentially sound anticancer nanocomposites. Chitosan nanoparticles loaded with 5-FU have been shown to exhibit cytotoxicity equivalent to 5-FU injections against gastric carcinoma. At the level of inter- and intra-molecular interactions, the co-crystal approach has been found to be successful against colorectal cancer proteins. Because of the 5-FU ligand-like nature and its metal-binding potential, researchers have shifted attention toward the synergistic co-administration of gold complexes with this drug. Conclusions: This study highlighted the techniques used to improve the pharmacokinetics of 5-FU and that “nanocarriers” are a promising approach in this field. The conclusion is supported by solid evidence.",
keywords = "Delivery systems, nanocomposites, pharmacokinetic targeted potentials, prodrug",
author = "SZ. Iqbal and F. Jubeen and F. Sher",
note = "This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.",
year = "2019",
month = "9",
day = "23",
doi = "10.4103/JCRP.JCRP_10_19",
language = "English",
volume = "6",
pages = "155--161",
journal = "Journal of Cancer Research and Practice",
number = "4",

}

TY - JOUR

T1 - Future of 5-fluorouracil in cancer therapeutics, current pharmacokinetics issues and a way forward

AU - Iqbal, SZ.

AU - Jubeen, F.

AU - Sher, F.

N1 - This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

PY - 2019/9/23

Y1 - 2019/9/23

N2 - Background: In addition to exhibiting antitumor potential, antitumor drugs exhibit toxicity due to a poor pharmacokinetic profile. An enormous amount of research has been carried out and is still ongoing to obtain more targeted, potent, and safe drugs to treat cancer, and pharmacokinetic evaluations of anticancer drugs are needed. Objectives: The present review examined different delivery systems and methodologies designed in recent years to investigate the pharmacokinetics of the anticancer drug, 5-fluorouracil (5-FU). These methodologies highlight how the issues of bioavailability, absorption, half-life, targeted neoplastic cell potential, and high therapeutic index of 5-FU are resolved. Results: A number of naturally occurring macromolecules such as modified starch, porphyran, peptides, and folic acids have been found to be successful in vitro to improve the permeability and retention effect of 5-FU against solid tumors. A promising approach for targeted 5-FU delivery to oncoproteins has resulted in a number of potentially sound anticancer nanocomposites. Chitosan nanoparticles loaded with 5-FU have been shown to exhibit cytotoxicity equivalent to 5-FU injections against gastric carcinoma. At the level of inter- and intra-molecular interactions, the co-crystal approach has been found to be successful against colorectal cancer proteins. Because of the 5-FU ligand-like nature and its metal-binding potential, researchers have shifted attention toward the synergistic co-administration of gold complexes with this drug. Conclusions: This study highlighted the techniques used to improve the pharmacokinetics of 5-FU and that “nanocarriers” are a promising approach in this field. The conclusion is supported by solid evidence.

AB - Background: In addition to exhibiting antitumor potential, antitumor drugs exhibit toxicity due to a poor pharmacokinetic profile. An enormous amount of research has been carried out and is still ongoing to obtain more targeted, potent, and safe drugs to treat cancer, and pharmacokinetic evaluations of anticancer drugs are needed. Objectives: The present review examined different delivery systems and methodologies designed in recent years to investigate the pharmacokinetics of the anticancer drug, 5-fluorouracil (5-FU). These methodologies highlight how the issues of bioavailability, absorption, half-life, targeted neoplastic cell potential, and high therapeutic index of 5-FU are resolved. Results: A number of naturally occurring macromolecules such as modified starch, porphyran, peptides, and folic acids have been found to be successful in vitro to improve the permeability and retention effect of 5-FU against solid tumors. A promising approach for targeted 5-FU delivery to oncoproteins has resulted in a number of potentially sound anticancer nanocomposites. Chitosan nanoparticles loaded with 5-FU have been shown to exhibit cytotoxicity equivalent to 5-FU injections against gastric carcinoma. At the level of inter- and intra-molecular interactions, the co-crystal approach has been found to be successful against colorectal cancer proteins. Because of the 5-FU ligand-like nature and its metal-binding potential, researchers have shifted attention toward the synergistic co-administration of gold complexes with this drug. Conclusions: This study highlighted the techniques used to improve the pharmacokinetics of 5-FU and that “nanocarriers” are a promising approach in this field. The conclusion is supported by solid evidence.

KW - Delivery systems

KW - nanocomposites

KW - pharmacokinetic targeted potentials

KW - prodrug

UR - http://www.ejcrp.org/article.asp?issn=2311-3006;year=2019;volume=6;issue=4;spage=155;epage=161;aulast=Iqbal

U2 - 10.4103/JCRP.JCRP_10_19

DO - 10.4103/JCRP.JCRP_10_19

M3 - Article

VL - 6

SP - 155

EP - 161

JO - Journal of Cancer Research and Practice

JF - Journal of Cancer Research and Practice

IS - 4

ER -